Division of Rheumatology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
Division of Rheumatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu, Korea.
Korean J Intern Med. 2023 Jan;38(1):113-124. doi: 10.3904/kjim.2021.146. Epub 2021 Aug 20.
BACKGROUND/AIMS: This study aims to evaluate the incidence of malignancy in patients with rheumatoid arthritis (RA) and to investigate risk factors for such in a nationwide, population-based cohort.
In a large, prospective, observational cohort study, 5,077 patients with RA were enrolled from July 2009 to December 2011 and followed until February 2017. Standardized incidence ratios (SIRs) for malignancy were calculated using age- and sex-specific cancer rates in the Korean general population. Poisson regression was used to identify the risk of incident malignancy.
The cohort included 5,023 participants with RA contributing 16,689 person-years of follow-up. A total of 148 malignancies were recorded. The risks of stomach cancer (SIR, 0.41; 95% confidence interval [CI], 0.21 to 0.74), colon cancer (SIR, 0.13; 95% CI, 0.03 to 0.37), and lung cancer (SIR, 0.35; 95% CI, 0.14 to 0.72) were lower in RA patients than in the general population. Poisson regression modeling demonstrated that the malignancy risk was more than two-fold greater in patients with thyroid disease than in those without thyroid disease. Hydroxychloroquine therapy was associated with a reduced risk (relative risk, 0.39; 95% CI, 0.189 to 0.801) of malignancy development.
The overall risk of malignancy in patients with RA is decreased relative to in the general population. In particular, stomach, colon, and lung cancers in Korean RA patients are less common, while brain and central nervous system cancers in male RA patients are more frequent. The patients with thyroid disease and longer RA disease duration were at increased risk for developing malignancy, while hydroxychloroquine users were at lower risk.
背景/目的:本研究旨在评估类风湿关节炎(RA)患者恶性肿瘤的发生率,并在全国范围内进行基于人群的队列研究中探讨其相关风险因素。
在一项大型前瞻性观察性队列研究中,我们于 2009 年 7 月至 2011 年 12 月期间招募了 5077 例 RA 患者,并随访至 2017 年 2 月。使用韩国普通人群中年龄和性别特异性癌症发病率计算恶性肿瘤的标准化发病比(SIR)。使用泊松回归确定新发恶性肿瘤的风险。
该队列包括 5023 名 RA 患者,共随访 16689 人年。共记录了 148 例恶性肿瘤。RA 患者的胃癌(SIR,0.41;95%置信区间 [CI],0.21 至 0.74)、结肠癌(SIR,0.13;95%CI,0.03 至 0.37)和肺癌(SIR,0.35;95%CI,0.14 至 0.72)的风险低于普通人群。泊松回归模型表明,与无甲状腺疾病的患者相比,甲状腺疾病患者的恶性肿瘤风险增加了两倍以上。羟氯喹治疗与恶性肿瘤发病风险降低相关(相对风险,0.39;95%CI,0.189 至 0.801)。
RA 患者恶性肿瘤的总体风险相对较低。特别是,韩国 RA 患者的胃癌、结肠癌和肺癌较为少见,而男性 RA 患者的脑和中枢神经系统癌症更为常见。患有甲状腺疾病和 RA 病程较长的患者恶性肿瘤发病风险增加,而使用羟氯喹的患者风险降低。